Safety and stability of retrovirally transduced chimeric antigen receptor T cells

Immunotherapy

Volumn 4, Issue 9, 2012, Pages 899-902

  Colovos, Christos ^a   Villena Vargas, Jonathan ^a   Adusumilli, Prasad S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

adoptive cell therapy; chimeric antigen receptor; HIV; insertional mutagenesis; retroviral vector transduction

Indexed keywords

RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR;

CELL PROLIFERATION; DRUG SAFETY; DRUG STABILITY; EX VIVO STUDY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; NOTE; PRIORITY JOURNAL; RETROVIRUS; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM;

EID: 84867381583     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.91     Document Type: Note

References (21)

1. Baum C. Gene therapy for SCID-X1: focus on clinical data. Mol. Ther. 19(12), 2103-2104 (2011).
2. Riviere I, Dunbar CE, Sadelain M. Hematopoietic stem cell engineering at a crossroads. Blood 119(5), 1107-1116 (2012).
3. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin Immunol. 21(2), 215-223 (2009).
4. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365(8), 725-733 (2011).
5. Brentjens RJ, Riviere I, Park JH et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118(18), 4817-4828 (2011).
6. Kochenderfer JN, Dudley ME, Feldman SA et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119(12), 2709-2720 (2012).
7. Scholler J, Brady TL, Binder-Scholl G et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci. Transl Med. 4(132), 132-153 (2012).
8. Mitsuyasu RT, Anton PA, Deeks SG et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus-infected subjects. Blood 96(3), 785-793 (2000). (Pubitemid 30616838)
9. Deeks SG, Wagner B, Anton PA et al. A Phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol. Ther. 5(6), 788-797 (2002). (Pubitemid 34619072)
10. Brady T, Roth SL, Malani N et al. A method to sequence and quantify DNA integration for monitoring outcome in gene therapy. Nucleic Acids Res. 39(11), e72 (2011).
11. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science 300(5626), 1749-1751 (2003). (Pubitemid 36712571)
12. Bonnet D. Cancer stem cells: lessons from leukaemia. Cell Prolif. 38(6), 357-361 (2005). (Pubitemid 41746368)
13. Recchia A, Bonini C, Magnani Z et al. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc. Natl Acad. Sci. USA 103(5), 1457-1462 (2006). (Pubitemid 43191187)
14. Heslop HE, Slobod KS, Pule MA et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115(5), 925-935 (2010).
15. Westwood JA, Murray WK, Trivett M et al. Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice. Gene Ther. 15(14), 1056-1066 (2008). (Pubitemid 351927696)
16. Newrzela S, Cornils K, Li ZX et al. Resistance of mature T cells to oncogene transformation. Blood 112(6), 2278-2286 (2008).
17. Chmielewski M, Rappl G, Hombach AA, Abken H. T cells redirected by a CD3zeta chimeric antigen receptor can establish self-antigen-specific tumour protection in the long term. Gene Ther. doi:10.1038/gt.2012.21 (2012) (Epub ahead of print).
18. Gattinoni L, Finkelstein SE, Klebanoff CA et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202(7), 907-912 (2005). (Pubitemid 41396891)
19. Pegram HJ, Lee JC, Hayman EG et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119(18), 4133-4141 (2012).
20. Sadelain M, Papapetrou EP, Bushman FD. Safe harbours for the integration of new DNA in the human genome. Nat. Rev. Cancer 12(1), 51-58 (2012).
21. Gattinoni L, Lugli E, Ji Y et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 17(10), 1290-1297 (2011).